Enzo Biochem Reports Third Quarter Results, Including Strong Revenue Growth At Clinical Labs Reflecting Increasing Volume And Greater Molecular Diagnostic Activity
NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) today reported results for the fiscal quarter and nine months ended April 30, 2015.
Highlights:
•Enzo Clinical Labs’ third quarter revenues grew to $15.7 million or 8% ahead of the prior year period; operating margins of 38% rose 500 basis points from the prior year, and 100 bps sequentially.
Help employers find you! Check out all the jobs and post your resume.
Highlights:
•Enzo Clinical Labs’ third quarter revenues grew to $15.7 million or 8% ahead of the prior year period; operating margins of 38% rose 500 basis points from the prior year, and 100 bps sequentially.
Help employers find you! Check out all the jobs and post your resume.